Biosynexus Incorporated Report issue

For profit Phase 3
Founded: Gaithersburg MD United States (1999)
Status: Defunct (2005)

Organization Overview

First Clinical Trial
2001
NCT00636285
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

pagibaximab (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacteremia (Phase 3)

Birth Weight (Phase 3)

Sepsis (Phase 3)

Staphylococcal Infections (Phase 3)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1